Goldman Sachs analysts added Bayer (BAYRY) to the firm’s European Conviction List as part of its monthly update. Goldman expects Bayer’s litigation overhang, which has weighed on shares since 2018, to be significantly reduced in the first half of 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer Tests Talcid in Real-World Acid Rebound Study: What It Means for BAYRY Investors
- Bayer Backs AskBio Gene Therapy Push in Pompe Disease: Early Trial Update and Investor Takeaways
- Bayer price target raised to EUR 41 from EUR 30.40 at Berenberg
- Bayer price target raised to EUR 40 from EUR 34 at HSBC
- Bayer upgraded to Overweight from Neutral at JPMorgan